Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 407, Issue 3, Pages 525-530Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2011.03.051
Keywords
Infliximab; Tumor necrosis factor-alpha; Breast cancer; MDA-MB-231; Bone metastasis
Categories
Funding
- Grants-in-Aid for Scientific Research [23592183] Funding Source: KAKEN
Ask authors/readers for more resources
In the evolution of cancer, tumor necrosis factor-alpha (TNF-alpha) plays a paradoxical role. High doses induce significant anticancer effects, but conversely, physiologic and pathologic levels of TNF-alpha may be involved in cancer promotion, tumor growth, and metastasis. Infliximab is a chimeric murine monoclonal antibody that binds with high affinity to soluble and membrane TNF-alpha and inhibits binding of TNF-alpha to its receptors. In the present study, we investigated the effect of infliximab, a TNF-alpha antagonist, on breast cancer aggressiveness and bone metastases. Infliximab greatly reduced cell motility and bone metastases in a metastatic breast cancer cell line, MDA-MB-231. The mechanism of bone metastasis inhibition involved decreased expression of CXC chemokine receptor 4 (CXCR4) and increased expression of decorin, which is the prototype of an expanding family of small leucine-rich proteoglycans. These results suggest a novel role for TNF-alpha inhibition in the reduction or prevention of bone metastases in this breast cancer model. Our study suggests that inhibition of TNF-alpha using infliximab may become a preventive therapeutic option for breast cancer. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available